Pediatrics

Q99. Discuss Scurvy (Vitamin C deficiency) and Infantile Beriberi (Thiamine deficiency), including radiological features and acute cardiac presentation.

Scurvy (Vitamin C Deficiency)

Pathophysiology: Vitamin C is an essential cofactor for collagen synthesis (hydroxylation of proline and lysine residues, essential for normal collagen cross-linking). Deficiency produces widespread connective tissue fragility, particularly affecting bone (collagen-rich osteoid matrix) and blood vessels (explaining the characteristic bleeding tendency).

Radiological Features

• Frankel's line — dense, radiopaque, transverse metaphyseal line (preserved calcification of collagen-poor cartilage matrix)
• Trümmerfeld zone (scurvy zone) — lucent band beneath Frankel's line, the zone of deficient, weakened osteoid/bone matrix
• Pelkan's spur — lateral spur-like metaphyseal projection, from localized structural weakness and marginal fracture/displacement
• Subperiosteal hemorrhage — classic finding from vascular fragility, elevating the periosteum, a source of significant pain

Clinical Features

Irritability, poor feeding, pseudoparalysis of the limbs (pain-related, from subperiosteal hemorrhage — an important mimicker to distinguish from true neurological/orthopedic paralysis), gum swelling/bleeding (once teeth erupt), and poor wound healing in severe/prolonged deficiency.

Infantile Beriberi (Thiamine/Vitamin B1 Deficiency)

Pathophysiology: Thiamine is an essential cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase, central to aerobic ATP generation. Deficiency particularly affects high metabolic-demand tissues (cardiac, neural). In infants, most commonly related to maternal thiamine deficiency (exclusively breastfed infant of a deficient mother), particularly relevant in polished-rice-predominant diets (thiamine concentrated in rice bran/husk, removed during polishing).

Q100. Discuss Lysosomal Storage Disorders: Gaucher Disease and Niemann-Pick Disease, including enzyme defects, clinical/radiological features, and treatment.

Gaucher Disease

Pathophysiology: Deficiency of glucocerebrosidase (acid beta-glucosidase), the lysosomal enzyme degrading glucocerebroside (generated from normal cell membrane turnover, particularly senescent blood cells). Deficiency causes progressive glucocerebroside accumulation within lysosomes of macrophages, producing characteristic lipid-laden "Gaucher cells" ("crumpled tissue paper" cytoplasm) that infiltrate bone marrow, spleen, liver, and, in certain subtypes, the CNS.

Types of Gaucher Disease

Clinical Features

Massive hepatosplenomegaly (splenomegaly often striking; hypersplenism-related anemia/thrombocytopenia), bone crises (acute, severe pain from vaso-occlusive-type events within infiltrated marrow, mimicking osteomyelitis or a sickle cell vaso-occlusive crisis).

Erlenmeyer Flask Deformity

A characteristic, classic radiological finding — abnormal undertubulation/failure of normal metaphyseal remodeling at the distal femur (and other long bones), producing a distinctive flared, flask-like appearance. Classically and most strongly associated with Gaucher disease, though can be seen (less characteristically) in a few other conditions.

Treatment

Enzyme Replacement Therapy (ERT) with recombinant glucocerebrosidase (imiglucerase and related preparations) has transformed management for Type 1 specifically — substantial benefit for hepatosplenomegaly, cytopenias, and bone disease, but does not effectively cross the blood-brain barrier (limited benefit for Types 2/3 neurological manifestations). Substrate Reduction Therapy (miglustat, eliglustat) reduces glucocerebroside synthesis, an orally-administered alternative/adjunct to ERT.

Niemann-Pick Disease

Classic forms (Types A and B) caused by deficiency of acid sphingomyelinase, causing sphingomyelin accumulation within lysosomes of macrophages and, in Type A, neurons.

Q101. Discuss Human Milk Composition and Fortification, including preterm vs term breast milk vs cow's milk, and indications for Human Milk Fortifiers.

Nutritional Comparison

Preterm Breast Milk

Breast milk from mothers who deliver preterm is not simply identical, "immature" term breast milk, but shows specific, physiologically adaptive compositional differences suited to the preterm infant's distinct needs — typically higher protein, sodium, and chloride content, and somewhat higher fat content, particularly in the initial weeks postpartum. This appears to be a physiologically appropriate maternal adaptation, though even this elevated composition is generally still inadequate to fully meet the very high nutrient demands of the extremely preterm/very low birth weight infant — the fundamental rationale for fortification.

Term Breast Milk vs Cow's Milk

Human Milk Fortifiers (HMF)

Indications

Added to expressed breast milk specifically for preterm, very low birth weight infants, given the recognized inadequacy of even preterm-adapted breast milk alone to meet high requirements for protein, calcium, phosphate, and other minerals/vitamins — needed for adequate postnatal growth and bone mineralization, since most fetal mineral accretion normally occurs in the third trimester (a period the preterm infant misses) — while preserving the invaluable immunological and bioactive benefits of breast milk itself.

Composition and Use

Available in powdered and liquid formulations, typically adding concentrated protein, calcium, phosphate, additional calories, vitamins, and trace minerals. Fortification is typically initiated once a defined enteral feeding volume threshold is reached (confirming feeding tolerance with unfortified breast milk first), and continued through the period of most rapid catch-up growth need — typically until a defined weight or approaching term-equivalent age, individualized based on ongoing growth monitoring.

Q102. Discuss Trace Element Deficiencies: Menkes Kinky Hair Disease (Copper), Keshan Disease (Selenium), and Congenital Iodine Deficiency Syndrome.

Menkes Kinky Hair Disease – Copper Deficiency/Transport Disorder

X-linked recessive disorder caused by mutations in ATP7A (closely related to, though functionally distinct from, ATP7B responsible for Wilson disease). ATP7A is required for intestinal copper absorption and cellular distribution/utilization; deficiency causes severe systemic copper deficiency despite potentially normal/elevated dietary intake, since the problem is one of transport/utilization rather than availability.

Clinical features: characteristic "kinky"/"steely" hair (pili torti — sparse, brittle, twisted hair, reflecting copper's cofactor role in lysyl oxidase, needed for collagen/elastin cross-linking), severe progressive neurodegeneration, hypotonia, seizures, and characteristic vascular abnormalities (arterial tortuosity). Early, typically fatal outcome in infancy/early childhood despite attempted treatment (subcutaneous copper histidine therapy, most effective if initiated very early, ideally presymptomatically in an at-risk sibling identified through family screening).

Keshan Disease – Selenium Deficiency

A distinctive, geographically-clustered endemic cardiomyopathy historically described predominantly in specific regions of China with severe environmental selenium deficiency (low soil selenium translating to low food selenium content). Selenium is an essential cofactor for glutathione peroxidase, a key antioxidant enzyme protecting cellular membranes (including cardiac myocytes) from oxidative damage. The clinical syndrome is classically described as precipitated/exacerbated by concurrent viral infection (particularly certain Coxsackievirus strains), suggesting an interaction between selenium-deficiency-related oxidative vulnerability and an infectious trigger.

Presents with dilated cardiomyopathy and heart failure. Selenium supplementation as a population-level public health intervention has demonstrated significant efficacy in reducing disease incidence in historically affected regions.

Congenital Iodine Deficiency Syndrome

The most severe end of the spectrum of iodine deficiency disorders, resulting from severe maternal iodine deficiency during pregnancy, causing inadequate fetal thyroid hormone availability during the critical period of fetal brain development. Presents with the combination of severe, irreversible intellectual disability, along with characteristic features including deaf-mutism, spasticity/motor abnormalities, and, in some presentations, signs of hypothyroidism (the classic "endemic cretinism" presentation spans a spectrum from predominantly neurological to predominantly myxedematous/hypothyroid phenotype).

Q103. Discuss Steroid-Resistant Nephrotic Syndrome (SRNS): definition, the role of genetic testing, biopsy indications, and treatment approach.

Definition and the Central Conceptual Shift

SRNS is defined as persistence of significant proteinuria despite an adequate 4-week trial of daily high-dose corticosteroid therapy (in contrast to Steroid-Sensitive Nephrotic Syndrome, which achieves remission within this window). The single most important conceptual shift in contemporary SRNS management is the recognition that SRNS is not a single disease but a heterogeneous syndrome with fundamentally different underlying mechanisms — a substantial proportion, particularly in early-onset or familial disease, reflects an underlying monogenic structural defect in the podocyte/glomerular filtration barrier, rather than an immune-mediated process.

Genetic Testing Panel

Genetic testing has become a central, increasingly first-line component of SRNS evaluation, rather than a last-resort investigation:

• NPHS1 (nephrin) — responsible for Congenital Nephrotic Syndrome of the Finnish type; massive proteinuria from birth/very early infancy; prototype monogenic podocytopathy
• NPHS2 (podocin) — the most commonly identified genetic cause of SRNS in many populations, particularly childhood-onset, often familial (autosomal recessive) SRNS
• PODXL and numerous other podocyte-structural/slit-diaphragm-associated genes, reflecting substantial genetic heterogeneity

A positive genetic result confirms a structural rather than immune-mediated mechanism, predicts non-response to immunosuppression (allowing avoidance of unnecessary toxicity), and importantly informs prognosis after kidney transplantation — genetic SRNS generally does not recur in the transplanted kidney (defect resides in native podocytes, not a circulating immune factor), a favorable distinguishing feature from non-genetic SRNS, which carries significant recurrence risk.

Kidney Biopsy Indications

Renal biopsy remains essential, performed alongside genetic testing — most commonly revealing Focal Segmental Glomerulosclerosis (FSGS) or, less commonly, Diffuse Mesangial Sclerosis. Generally indicated in essentially all children with confirmed steroid resistance, given the diagnostic/prognostic value of histopathological classification.

Calcineurin Inhibitors – First-Line Immunosuppressive Therapy

For children without an identified monogenic cause, Calcineurin Inhibitors (Tacrolimus or Cyclosporine) are first-line. Tacrolimus is increasingly preferred over cyclosporine given a more favorable cosmetic profile (less gingival hyperplasia and hirsutism). Both require careful therapeutic drug level monitoring given narrow therapeutic index and nephrotoxicity risk with prolonged use.

Biological Agents

Rituximab (anti-CD20 monoclonal antibody, depleting B-lymphocytes) has an emerging, evolving role, particularly for calcineurin inhibitor-resistant or -dependent disease, reflecting a rationale that aberrant B-cell-mediated immunity may underlie a subset of non-genetic SRNS — a "recent advances" area of active research.

Overall Management Algorithm

Confirm steroid resistance → genetic testing and kidney biopsy in parallel → if genetic cause identified: avoid/minimize immunosuppression, focus on supportive management (ACE inhibitor/ARB for proteinuria, nephrotic complication management) and plan transplantation with reassurance regarding low recurrence risk → if no genetic cause identified: proceed to calcineurin inhibitor-based immunosuppression, escalating to rituximab or other agents for refractory disease.

Q104. Discuss Steroid-Sensitive Nephrotic Syndrome (SSNS): first-episode treatment protocol, and definitions of FRNS and SDNS.

First Episode Treatment Protocol

Following current IPNA/ISPN-aligned guidance: daily oral prednisolone (typically 60 mg/m²/day or 2 mg/kg/day, maximum 60 mg/day) for 4–6 weeks, followed by alternate-day dosing (typically 40 mg/m² or 1.5 mg/kg on alternate days) for a further period — total treatment duration for a first episode generally recommended at approximately 12 weeks (extended beyond shorter, historically-used courses, given evidence of reduced relapse rates).

Remission (typically urine protein trace/nil, or urine albumin:creatinine ratio below a defined threshold, for 3 consecutive days) is achieved in the great majority of children within the 4-week induction window, defining them as steroid-sensitive.

Definitions of Relapse Categories

Management Implications of Relapse Category

Children meeting FRNS or SDNS criteria are candidates for steroid-sparing agents, given the cumulative toxicity burden (growth impairment, obesity, cataracts, osteoporosis) of repeated/prolonged corticosteroid courses. Steroid-sparing options include:

• Levamisole — favorable safety profile, often reasonable first-line for FRNS
• Mycophenolate mofetil
• Calcineurin inhibitors (tacrolimus/cyclosporine)
• Rituximab — for more refractory cases

Choice is individualized based on relapse severity/frequency, prior treatment response, and accumulated steroid toxicity burden. Each relapse episode is treated with a standard, shorter course of daily prednisolone until remission, followed by a tapering course.

Q105. Discuss Acute Kidney Injury (AKI) in children: pediatric KDIGO staging, etiology, biomarkers, fluid overload management, and RRT indications.

KDIGO Classification for Pediatric AKI

This framework is directly, structurally analogous to the adult KDIGO AKI classification, with the pediatric-specific eGFR-based Stage 3 criterion representing a notable pediatric-specific addition.

Etiology – Pre-renal / Intrinsic / Post-renal Framework

• Pre-renal — most common category in children; reduced renal perfusion without intrinsic parenchymal damage (dehydration, sepsis/distributive shock, cardiac failure, significant hemorrhage); potentially reversible if promptly corrected
• Intrinsic — direct parenchymal injury: acute tubular necrosis (prolonged pre-renal insult, nephrotoxin exposure, severe hemolysis/rhabdomyolysis), glomerulonephritis, interstitial nephritis, hemolytic uremic syndrome
• Post-renal — obstruction to urinary outflow (posterior urethral valves being a particularly important pediatric-specific cause, along with nephrolithiasis)

Biomarkers

NGAL (Neutrophil Gelatinase-Associated Lipocalin) and KIM-1 (Kidney Injury Molecule-1) are emerging early tubular injury biomarkers — both rise substantially earlier than serum creatinine (a delayed, functional marker rising only after significant nephron loss), offering earlier AKI recognition, particularly valuable in high-risk populations (post-cardiac surgery, critically ill PICU children).

Fluid Overload Management

Fluid overload is an independent, important determinant of outcome in pediatric AKI. Fluid overload percentage (cumulative fluid balance relative to admission body weight) is used both as a monitoring parameter and, in some protocols, a specific threshold trigger for escalating to RRT — making restrictive fluid administration and diuretic therapy a central, active management priority.

Indications for Renal Replacement Therapy

Following the "AEIOU" framework (severe Acidosis, refractory Electrolyte abnormality/hyperkalemia, dialyzable Intoxication, refractory fluid Overload, significant Uremia):

• Peritoneal Dialysis — particularly favored in younger infants/smaller children and resource-limited settings (technical simplicity, good hemodynamic tolerability)
• Continuous Renal Replacement Therapy (CRRT) — preferred in hemodynamically unstable, critically ill children (PICU)
• Intermittent Hemodialysis — used in hemodynamically stable children needing rapid solute clearance (severe hyperkalemia, toxin removal)

Q106. Discuss Hemolytic Uremic Syndrome (HUS): the clinical triad, typical (STEC-HUS) vs atypical (complement-mediated) HUS, distinguishing features, and eculizumab therapy.

The Clinical Triad

Both typical and atypical HUS present with the same triad: Microangiopathic Hemolytic Anemia (MAHA) (schistocytes/fragmented red cells on smear), thrombocytopenia (platelet consumption within the microvascular thrombotic process), and Acute Kidney Injury — reflecting the shared underlying pathophysiology of thrombotic microangiopathy.

Typical HUS (STEC-HUS) – Pathogenesis

The overwhelming majority of pediatric HUS represents typical, or STEC-HUS, triggered by infection with Shiga toxin-producing E. coli (most classically serotype O157:H7), typically following bloody diarrhea (undercooked ground beef being the classically taught source). Shiga toxin enters systemic circulation and binds Gb3 receptors, densely expressed on renal endothelial cells (explaining the pronounced renal tropism), causing direct endothelial injury and triggering microvascular thrombosis.

Typical HUS is generally self-limited, with the great majority of children achieving complete renal recovery, though a minority require dialysis acutely or develop long-term chronic kidney impairment.

Atypical HUS (aHUS) – Complement Dysregulation

A fundamentally different, genetically-driven disorder of complement regulation — mutations in genes encoding complement regulatory proteins (Complement Factor H, Complement Factor I, Membrane Cofactor Protein/CD46), or gain-of-function mutations in complement activating components. The shared mechanism is uncontrolled activation of the alternative complement pathway, without a preceding Shiga-toxin diarrheal trigger (though episodes can be precipitated by intercurrent infection, pregnancy, or other complement-activating stress).

Distinguishing Typical from Atypical HUS

• Absence of preceding bloody diarrheal prodrome (raises suspicion for aHUS, though not definitive)
• Atypical age of presentation (aHUS can occur in neonates or present for the first time in adulthood)
• Family history of HUS or unexplained renal disease
• Recurrent episodes

Laboratory confirmation: stool testing for Shiga toxin/STEC (supports typical HUS); complement pathway functional and genetic testing where aHUS is suspected.

Eculizumab Therapy

Eculizumab, a monoclonal antibody targeting and blocking complement component C5 (preventing formation of the terminal membrane attack complex), represents a genuinely transformative, targeted therapy for atypical HUS — in sharp contrast to the purely supportive management (fluid/electrolyte management, blood product support, dialysis as needed) that is the mainstay for typical HUS, where no equivalent targeted therapy exists.

Q107. Discuss Hypertension in Children: blood pressure measurement technique, 2017 AAP definitions, secondary hypertension evaluation, and treatment.

Blood Pressure Measurement Methodology

Accurate measurement requires: an appropriately-sized cuff (bladder width ≈40% of arm circumference at the midpoint between olecranon and acromion — an undersized cuff produces a falsely elevated reading), the child seated quietly for at least 5 minutes with the arm supported at heart level, and, given the white-coat effect, a diagnosis of hypertension generally requires elevated readings confirmed on at least 3 separate occasions.

2017 AAP Definitions

Diagnostic Evaluation for Secondary Hypertension

Particularly in younger children and those with more severe hypertension, a secondary cause is more likely than in adults. Evaluation typically includes: renal function and electrolytes, urinalysis, renal ultrasound (structural abnormality, kidney size/symmetry suggesting renal artery stenosis or reflux nephropathy), and, where indicated, further targeted evaluation for renovascular, endocrine, or cardiovascular (coarctation) causes.

Stepped Care Treatment

Lifestyle modification (weight management, dietary sodium reduction, increased physical activity) is the foundational first step, particularly for obesity-associated primary/essential hypertension. Pharmacological therapy is added for Stage 2 hypertension, symptomatic hypertension, target organ damage, secondary hypertension, or inadequate control with lifestyle alone — with ACE inhibitors/ARBs commonly first-line (particularly for children with underlying proteinuric renal disease), calcium channel blockers, and diuretics as other standard options.

Q108. Discuss Renal Tubular Acidosis (RTA) Types I, II, and IV, including the urine anion gap as a diagnostic tool.

Proximal (Type II) RTA

A defect in proximal tubular bicarbonate reabsorption causes excessive urinary bicarbonate loss and consequent metabolic acidosis. The acidosis can be relatively mild/self-limited once a new, lower steady-state serum bicarbonate is reached. Frequently occurs as part of broader Fanconi syndrome (generalized proximal tubular dysfunction).

Distal (Type I) RTA

A defect in distal tubular hydrogen ion secretion impairs urinary acidification even with systemic acidosis — the defining feature is inability to lower urine pH below 5.5. Classically associated with hypokalemia and, importantly, nephrocalcinosis and nephrolithiasis (persistently alkaline urine promoting calcium phosphate stone formation).

Hyperkalemic (Type IV) RTA

Results from aldosterone deficiency or renal tubular resistance to aldosterone, impairing both potassium and hydrogen ion secretion — defining feature is hyperkalemia with a typically mild acidosis. Causes include congenital adrenal hyperplasia and various causes of aldosterone resistance.

Urine Anion Gap – Key Distinguishing Tool

Urine Anion Gap = Urine [Na♠ + K♠] − [Cl−], an indirect surrogate for urinary ammonium excretion.

• Negative gap — appropriately increased ammonium excretion; normal renal acid-handling responding to acidosis (Type II RTA, or extrarenal causes like diarrhea)
• Positive gap — inappropriately reduced ammonium excretion despite systemic acidosis; points toward distal (Type I) RTA

Alkali Therapy

Treatment centers on alkali replacement (sodium bicarbonate or citrate) across all types, to correct acidosis and support normal growth (chronic acidosis itself impairs growth). Required dose is typically substantially higher in Type II RTA than Type I, given ongoing proximal bicarbonate wasting. Type IV additionally requires potassium management (dietary restriction, binding resins) and, where aldosterone deficiency is the cause, mineralocorticoid replacement (fludrocortisone).